Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies

Wang, Hao; Li, Lixia; Qing, Xiaochun; Zhang, Shouyan; Li, Shulong

doi:10.1155/2020/8138764

Cited by 10 publications

(36 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 26 ] The QSYQ treatment course is divided into 1 to 4 weeks, 5 to 8 weeks, ≥9 weeks, and the number of corresponding studies is 29, 24, and 32 respectively. [ 11 ] For HF patients, it takes a certain period to receive TCM treatment before it can be effective. Moreover, TCM has advantages in the long-term prognosis of patients through overall adjustment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure

et al. 2021

View full text Add to dashboard Cite

Background: Heart failure (HF) has become a serious global public health issue due to its high incidence, high mortality and extremely low quality of life. According to several clinical trials, Qishen Yiqi Dripping pills (QSYQ) combined with routine western medicine treatment can further enhance the curative effect of HF patients. However, most of the trials are small in sample size and poor in quality, which can only provide limited evidence-based medicine. The existing systematic reviews of efficacy and safety has provided evidence for the clinical application of QSYQ to a certain extent, but there are still 3 major defects. Here, we will perform a systematic review and meta-analysis that include the randomized clinical trial (RCT) of CACT-IHF, apply meta-regression and subgroup analysis to cope with multiple confounding factors, and add the clinical efficacy standards of TCM, all-cause death and readmission rates as reliable efficacy evaluation indicators. The purpose of this study was to rigorously evaluate the clinical efficacy and safety of QSYQ in the complementary treatment of HF with a well-designed systematic review and meta-analysis. Methods: Following the strict search strategy, 9 databases will be searched to ensure a comprehensive search. We search the database from the establishment until November 30, 2020. This study will include RCTs of QSYQ in HF patients’ complementary treatment. Two searchers will independently draft and carry out the search strategy, and the third member will further complete it. Two members independently screen literature, extract data and cross-check, and solve different opinions through discussion or negotiation with the third member. The risk bias will be evaluated based on Cochrane tool of risk of bias. Meta-regression and subgroup analysis are used to check and deal with the heterogeneity. The data analysis will be conducted by the statistical software Stata 16.0. Results: The results of this research will be delivered in a peer-reviewed journal. Conclusion: This study expects to provide credible and scientific evidence for the efficacy and safety of QSYQ in HF's complementary treatment, and at the same time provide a convenient and effective choice for decision-makers and patients. Protocol registration number: INPLASY 2020120106. Ethical approval: Since this study is on the basis of published or registered RCTs, ethical approval and informed consent of patients are not required.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, none of a SR includes this trial in statistical analysis, not even the latest meta-analysis (MA) that includes 85 RCTs. [ 11 ]…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Then, the full text of 16 potential articles was further screened, of which one of our previous studies was excluded because it was an RCT. Finally, 14 systematic reviews (10,12,(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34) were included. The specific screening process is presented in Figure 1 and Supplementary material 2.…”

Section: Study Selectionmentioning

confidence: 99%

“…Table 2 summarizes the main characteristics of all included reviews. They were published between 2013 and 2021, with two studies (10,12) published in English and the remaining (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34) published in Chinese. All articles were published in peer-reviewed journals.…”

Section: Characteristics Of the Included Reviewsmentioning

confidence: 99%

The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses

Chen

Wang

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

ObjectivesEvidence from systematic reviews/meta-analyses about the efficacy and safety of Qishen Yiqi (QSYQ) dripping pills in chronic heart failure (CHF) remains unclear. This study comprehensively reviewed available systematic reviews on latest evidence to provide reliable information for the clinical use of QSYQ in CHF.MethodsThe systematic review was performed on studies retrieved from six major medical databases. Eligible studies were evaluated in terms of methodological quality and quality of evidence using the Assessment of Multiple Systematic review 2 (AMSTAR-2) tool, the Risk of Bias in Systematic Reviews (ROBIS) was used to assess the risk of bias, and the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) 2020 was utilized for assessing reporting quality. In addition, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to determine primary outcome indicators’ evidence quality.ResultsA total of 14 systematic reviews were included in this study, based on which it could be concluded that QSYQ combined with conventional medicine (CM) treatment tended to be superior to CM treatment alone in terms of improving cardiac function-related indices (e.g., increasing the left ventricular ejection fraction [LVEF] and reducing the left ventricular end-diastolic dimension [LVEDD] and left ventricular end-systolic internal diameter [LVESD]), improving the total effective rate and 6-min walking distance (6MWD), and reducing N-terminal pro-brain natriuretic peptide (NT-proBNP). Overall, no serious QSYQ-related adverse events were observed. However, the GRADE results showed “very low” to “moderate” evidence for these outcomes, with no high-quality evidence supporting them. Unsatisfactory results were obtained in terms of methodological quality, risk of bias and reporting quality after assessment using the AMSTAR-2, ROBIS, and PRISMA 2020, limited mainly by deficiencies in the following areas: registration of study protocols, explanation of the inclusion of randomized controlled trials (RCTs), complete and detailed search strategy, list of excluded literature, description of funding sources for inclusion in RCTs, investigation of the impact of risk of bias on the results of meta-analysis, and reporting of potential conflicts of interest.ConclusionThe efficacy and safety of QSYQ adjuvant therapy in CHF remain to be further clarified due to the lack of high-quality evidence provided by current systematic reviews.

show abstract

“…A number of studies have shown that combined treatment of Chinese and Western medicine can reduce the rehospitalization rate of patients with CHF, improve the quality of life, and improve the long-term prognosis. [ 7 – 9 ] Evidence from clinical studies of traditional Chinese medicine (TCM) is also used in the “Guidelines for the Diagnosis and Treatment of Heart Failure in China” in 2014 and 2018. [ 10 , 11 ]…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of Shenfuqiangxin pills in complementary treatment of chronic heart failure

et al. 2021

View full text Add to dashboard Cite

Background: As the last link in the chain of cardiovascular events, chronic heart failure (CHF) has high morbidity, high mortality, and poor prognosis. It is one of the main causes of death and disability worldwide. Shenfuqiangxin Pills (SFQX) is widely used as a Chinese herbal medicine (CHM) prescription for CHF, but there is still a lack of strict evidence-based medical evidence. Therefore, we make a protocol for evaluating the efficacy and safety of SFQX for CHF. Methods: According to the search strategy, randomized controlled trials (RCTs) of SFQX for CHF will be retrieved from 8 databases without limitation of publication date or language. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using software for traditional meta-analysis. Finally, using GRADE method to assess the strength of recommendations. Results: This study will evaluate the efficacy and safety of SFQX for CHF, thereby providing more evidence support for clinical decision-making in CHF. Conclusion: Our research will provide more references for the clinical medication of patients with CHF. Protocol registration number: INPLASY202110019

show abstract

Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies

Cited by 10 publications

References 30 publications

Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure

Efficacy and safety of Qishen Yiqi dripping pills as a complementary treatment for Heart Failure

The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses

Efficacy and safety of Shenfuqiangxin pills in complementary treatment of chronic heart failure

Contact Info

Product

Resources

About